Archived

Analysis of intellectual property considerations in developing and distributing a coronavirus vaccine

Background

Our remit is global and our interests correspondingly wide. The below are indicative rather than fully comprehensive questions of relevance for our work and are arranged into ten overlapping categories.

The dynamic nature of world events and diplomatic work around them mean that we often need research based insights to help anticipate, shape, manage and benefit from unfolding developments and possible futures. The synthesised expertise of researchers can help us make judgements in a policy environment where experimental trials and replicable results are often impossible or inappropriate.

Because time can be of the essence we value emerging results and insights shared via updates, short events, websites and similar, in advance of peer reviewed articles.

Next steps

Get in touch with fcocorrespondence@fco.gov.uk

Source

This question was published as part of the set of ARIs in this document:

FCO Areas of research interest coronavirus COVID 19 update May 2020 GOVUK

Related UKRI funded projects


  • Manufacturing research hub for a sustainable future: Vaccines for pandemic preparedness

    The Covid-19 pandemic continues to take a huge toll - an estimated 6.3m people have died including 178,000 in the UK. Globally 1.6bn students have missed school, 250m people will be pushed into extreme poverty and econom...

    Funded by: EPSRC

    Lead research organisation: University College London

    Why might this be relevant?

    The project focuses on vaccine development and manufacturing, but does not address intellectual property considerations.

  • The Future Vaccine Manufacturing Research Hub (Vax-Hub)

    Vaccines are the most successful public health initiative of the 20th century. They save millions of lives annually, add billions to the global economy and extended life expectancy by an average of 30 years. Even so, the...

    Funded by: EPSRC

    Lead research organisation: University College London

    Why might this be relevant?

    The project focuses on vaccine manufacturing and development, which is directly related to the question about intellectual property considerations in developing and distributing a coronavirus vaccine.

  • Future Vaccine Manufacturing Hub: Advancing the manufacture and deployment of cost effective vaccines

    Vaccine manufacturing systems have undergone evolutionary optimisation over the last 60 years, with occasional disruptions due to new technology (e.g. mammalian cell cultures replacing egg-based systems for seasonal infl...

    Funded by: EPSRC

    Lead research organisation: Imperial College London

    Why might this be relevant?

    The project addresses the challenges of improving and optimizing vaccine manufacturing processes, which is relevant to the question about intellectual property considerations in developing and distributing a coronavirus vaccine.

  • A Conditional System for Inexpensive Manufacture of Attenuated Vaccines

    Emerging infectious diseases (EIDs) with a potential for substantial and wide spread human mortality are an increasing threat to global stability. EIDs of global significance are most commonly caused by viruses - many of...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF PLYMOUTH

    Why might this be relevant?

    The project specifically addresses the development of a vaccine platform for targeting emerging viruses in low income countries, which aligns with the question on intellectual property considerations in developing and distributing a coronavirus vaccine.

  • The Future Vaccine Manufacturing Research Hub (Vax-Hub) - Additional Funding

    This grant provides additional funding for the EPSRC manufacturing hub: The Future Vaccine Manufacturing Research Hub (Vax-Hub) The funds will support training (e.g. related to GMP, sustainability and EDI); subcontracts ...

    Funded by: EPSRC

    Lead research organisation: University College London

  • Innovation and Complentary Capabilities for Vaccines

    The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to more quickly develop vaccines through greater global cooperation. £16 million will be invested to support the dev...

    Funded by: FIC

    Lead research organisation: Institute of Development Studies